Table 1 Patient characteristics

Sex (female)

154 (23.5)

 mean (SD), [range]

40.1 (12.1), [10–78]

 < 15

3 (0.5)

 ≥ 15–< 25

46 (7.0)

 ≥ 25–< 35

189 (28.8)

 ≥ 35–< 45

219 (33.4)

 ≥ 45–< 55

109 (16.6)

 ≥ 55–< 65

65 (9.9)

 ≥ 65

25 (3.8)

 mean (SD), [range]

7.46 (6.80), [0.1–49.0]

 < 5

268 (40.9)

 ≥ 5–< 10

159 (24.2)

 ≥ 10–< 15

95 (14.5)

 ≥ 15

77 (11.7)

 unknown

57 (8.7)

 mean (SD), [range]

6.63 (5.91), [0.0–36.0]

 < 5

294 (44.8)

 ≥ 5–< 10

166 (25.3)

 ≥ 10–< 15

86 (13.1)

 ≥ 15

60 (9.1)

 unknown

50 (7.6)

 severe

408 (62.2)

 moderate

201 (30.6)

 mild

36 (5.5)

 unknown

11 (1.7)

History of TB infection

35 (5.3)

Prophylactic anti-TB drug

242 (36.9)

History of HBV infection

6 (0.9)

 unknown

1 (0.2)

History of allergic disease

38 (5.8)

History of IFX use

31 (4.7)

 any symptoms

592 (90.2)

 oral aphthous ulcers

534 (81.4)

 genital ulcers

226 (34.5)

 skin lesions

392 (59.8)

 arthritis

171 (26.1)

 epididymitis

30 (4.6)

 central nervous system lesions

64 (9.8)

 intestinal tract lesions

67 (10.2)

 vascular lesions

20 (3.0)

 other symptoms

26 (4.0)

 unknown

5 (0.8)

 any comorbidity

360 (54.9)

 respiratory disease

10 (1.5)

 hepatic disease

35 (5.3)

 cardiac disease

10 (1.5)

 ocular disease

185 (28.2)

 kidney disease

23 (3.5)

 malignancy

2 (0.3)

 diabetes mellitus

31 (4.7)

 other diseases

200 (30.5)

 cyclosporine

251 (38.3)

  dose, median (Q1, Q3), mg/day, n = 242^a

168.24 (120.00, 200.00)

 glucocorticoids

239 (36.4)

  dose, median (Q1, Q3), mg/day, n = 235^a

13.07 (7.50, 20.00)

 colchicine

328 (50.0)

  dose, median (Q1, Q3), mg/day, n = 325^a

1.00 (1.00, 1.00)

Infliximab dose, median (Q1, Q3) [range], mg/kg

5.00 (5.00, 5.00) [3.4–6.4]